NorthWest Biotherapeutics Inc (NWBO)

[Umibe5690]

I think the answer, either way, is a win-win. If crossovers are living longer as well, but perhaps not as long as the early Tx, that is a good thing in any event even though there would possibly be de minimis curve separation. If it does not work, may be good for the trial but not so good for patients even though we know that there were only 3 resections, etc., etc. and the crossover population is not the same as the early Tx population.